Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?

Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0023424. doi: 10.1128/aac.00234-24. Epub 2024 May 24.

Affiliations

¹ Unit of Infectious Diseases, Department of Medical Sciences, University of Torino at the Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy.
² Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni, Verona, Italy.
³ Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.

No abstract available

Keywords: Mycobacterium; Mycobacterium avium; drug interactions; pharmacokinetics.

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Azithromycin* / therapeutic use
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium Infections, Nontuberculous / drug therapy
Mycobacterium Infections, Nontuberculous / microbiology
Nontuberculous Mycobacteria / drug effects
Rifampin* / therapeutic use

Substances

Rifampin
Azithromycin
Anti-Bacterial Agents